title: Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.
abstract: negative for the expression of estrogen receptor and progesterone receptor and HER2 amplification) has been limited to chemotherapy options. Neoadjuvant chemotherapy induces tumor shrinkage and improves the surgical outcomes of patients with locally advanced disease and also identifies those at high risk of disease relapse despite today's standard of care. By using pathologic complete response as a surrogate endpoint, novel treatment strategies can be efficiently assessed. Tissue analysis in the neoadjuvant setting is also an important research tool for the identification of chemotherapy resistance mechanisms and new therapeutic targets. In this paper, we review data on completed and ongoing neoadjuvant clinical trials in patients with TNBC and discuss treatment controversies that face clinicians and researchers when neoadjuvant chemotherapy is employed.
authors: Section of Breast Oncology, Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
authors: Foluso O
authors: FO
authors: Ademuyiwa
authors: Matthew J
authors: MJ
authors: Ellis
authors: Cynthia X
authors: CX
authors: Ma
references: Breast Cancer Res Treat. 2012 Nov;136(2):487-93
references: 23053638
references: Ann Surg. 2006 Feb;243(2):257-64
references: 16432360
references: Breast Cancer Res. 2007;9(5):R65
references: 17910759
references: Nature. 2012 Oct 4;490(7418):61-70
references: 23000897
references: Lancet Oncol. 2011 Sep;12(9):852-61
references: 21862407
references: J Nucl Med. 2012 Feb;53(2):249-54
references: 22241914
references: Ann Oncol. 2014 Jun;25(6):1122-7
references: 24669015
references: J Clin Oncol. 2005 Mar 10;23(8):1782-90
references: 15755986
references: Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
references: 11553815
references: J Clin Oncol. 2007 Jul 1;25(19):2650-5
references: 17602071
references: Breast Dis. 2010;32(1-2):73-84
references: 21778575
references: Nature. 2012 May 16;486(7403):400-4
references: 22722201
references: J Am Coll Surg. 1995 Mar;180(3):297-306
references: 7874340
references: J Clin Oncol. 2009 Feb 1;27(4):526-34
references: 19075286
references: Breast. 2003 Oct;12(5):320-7
references: 14659147
references: J Clin Oncol. 2007 May 20;25(15):2012-8
references: 17513805
references: J Clin Oncol. 2005 Apr 20;23(12):2694-702
references: 15837984
references: Cancer Res. 2006 May 1;66(9):4636-44
references: 16651414
references: Eur Radiol. 2004 Aug;14(8):1371-9
references: 14986052
references: J Clin Oncol. 2006 Mar 1;24(7):1037-44
references: 16505422
references: Lancet Oncol. 2010 Apr;11(4):358-65
references: 20189874
references: Lancet. 2010 Jul 24;376(9737):235-44
references: 20609467
references: Clin Cancer Res. 2007 Apr 15;13(8):2329-34
references: 17438091
references: Cancer Discov. 2013 Jan;3(1):27-34
references: 23319768
references: J Clin Oncol. 2002 Mar 15;20(6):1456-66
references: 11896092
references: J Clin Oncol. 2012 May 20;30(15):1796-804
references: 22508812
references: N Engl J Med. 2009 Jul 9;361(2):123-34
references: 19553641
references: Ann Oncol. 2010 May;21(5):961-7
references: 20211870
references: Ann Oncol. 2008 Nov;19(11):1847-52
references: 18567607
references: J Clin Oncol. 1998 Aug;16(8):2672-85
references: 9704717
references: J Clin Oncol. 2005 Sep 1;23(25):5983-92
references: 16087943
references: Nature. 2012 Jun 20;486(7403):405-9
references: 22722202
references: Ann Oncol. 2005 Jan;16(1):56-63
references: 15598939
references: Breast Cancer Res Treat. 2015 Nov;154(2):351-7
references: 26536871
references: Cancer. 2010 Sep 15;116(18):4227-37
references: 20549829
references: N Engl J Med. 2012 Jan 26;366(4):299-309
references: 22276820
references: J Clin Oncol. 2007 Oct 1;25(28):4414-22
references: 17785706
references: Am J Clin Oncol. 1983 Oct;6(5):599-604
references: 6613926
references: J Clin Oncol. 2010 Mar 1;28(7):1145-53
references: 20100965
references: Lancet. 2012 Feb 18;379(9816):633-40
references: 22257673
references: Nature. 2012 Apr 04;486(7403):395-9
references: 22495314
references: J Clin Oncol. 2003 Nov 15;21(22):4165-74
references: 14559892
references: Nature. 2012 Jun 10;486(7403):353-60
references: 22722193
references: Virchows Arch. 2009 Dec;455(6):461-7
references: 19911196
references: Am J Clin Oncol. 2013 Dec;36(6):540-4
references: 22868240
references: Breast Cancer Res Treat. 2010 Nov;124(1):133-40
references: 20697801
references: J Clin Oncol. 2009 Oct 1;27(28):4693-700
references: 19720916
references: N Engl J Med. 2012 Jan 26;366(4):310-20
references: 22276821
references: J Clin Oncol. 2008 Sep 10;26(26):4282-8
references: 18779615
references: J Clin Oncol. 2008 Mar 10;26(8):1275-81
references: 18250347
references: Oncogene. 2006 Jun 29;25(28):3994-4008
references: 16491124
references: J Clin Invest. 2011 Jul;121(7):2750-67
references: 21633166
references: Nature. 2012 Apr 18;486(7403):346-52
references: 22522925